XAIR - Beyond Air, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.15
-0.09 (-1.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.24
Open5.25
Bid5.06 x 900
Ask12.20 x 3000
Day's Range5.05 - 5.25
52 Week Range4.60 - 5.89
Volume5,329
Avg. Volume11,750
Market CapN/A
Beta (3Y Monthly)-0.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 12, 2019 - Nov 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.67
Trade prices are not sourced from all markets
  • GlobeNewswire

    Beyond Air™ Reports Financial Results for Fiscal First Quarter 2020

    Began trading under new ticker symbol, XAIR, on the NASDAQ stock exchange on July 15, 2019 Anticipate submitting a PMA for LungFit™* for the treatment of persistent pulmonary.

  • GlobeNewswire

    Beyond Air™ Participating at the BTIG Biotechnology Conference on August 12

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate in the BTIG Biotechnology Conference being held at the St. Regis Hotel in New York, NY on August 12, 2019. Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.

  • GlobeNewswire

    Beyond Air™ Schedules First Fiscal Quarter 2020 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y. and REHOVOT, Israel, July 30, 2019 -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing.